Comparative Study of the Quality of Life of Patients Suffering From OTOTOXICITY Due to Chemotherapy Based on Platinum Salts Fitted With a Hearing Aid Compared to Those Not Fitted.
Launched by INSTITUT DE CANCÉROLOGIE DE LORRAINE · Jun 29, 2023
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how using hearing aids can improve the quality of life for cancer patients who are experiencing hearing problems due to chemotherapy treatments that contain platinum. Many patients undergoing these treatments face side effects like hearing loss and ringing in the ears, which can be quite distressing. The aim of the study is to see if providing hearing aids to these patients can help them feel better and enjoy a higher quality of life while they continue their cancer treatment.
To participate in this study, you need to be an adult currently receiving platinum-based chemotherapy and experiencing hearing loss. You should also have a confirmed hearing issue from a hearing test. It’s important that you can follow the study guidelines and have signed the consent form. If you are pregnant, already have a hearing aid, or are facing certain other medical conditions, you may not be eligible. If you join the study, you can expect to receive a hearing aid and help with any related support, which may make your treatment experience more comfortable.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patient
- • Patient currently undergoing treatment with platinum-based chemotherapy and suffering from hypoacusia consistent with the treatment or presenting a worsening of already existing hypoacusis consistent with the start of treatment with platinum-based chemotherapy
- • Patient whose hypoacusis is confirmed by the audiometric test
- • Patient able and willing to follow all study procedures in accordance with the protocol.
- • Patient having understood, signed and dated the consent form
- • Patient affiliated to the social security system
- Exclusion Criteria:
- • Pregnant or breastfeeding woman
- • Persons deprived of liberty or under guardianship (including curatorship)
- • Impossibility of submitting to medical monitoring of the trial for geographical, social or psychological reasons
- • Patient with a contraindication to wearing hearing aids
- • Patient already fitted
- • Patient already included in a protocol including an experimental molecule
- • Patient who has not started treatment with platinum-based chemotherapy
- • Patient presenting only tinnitus without hearing loss
About Institut De Cancérologie De Lorraine
The Institut de Cancérologie de Lorraine (ICL) is a leading cancer research and treatment center in France, dedicated to advancing oncology through innovative clinical trials and comprehensive patient care. With a focus on multidisciplinary collaboration, ICL integrates cutting-edge research with clinical practice to enhance therapeutic outcomes and improve the quality of life for cancer patients. The institute is committed to fostering scientific discovery and translating findings into effective treatments, while adhering to the highest ethical standards in clinical research. Through its robust portfolio of clinical trials, ICL aims to contribute significantly to the understanding and management of various cancer types.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vandœuvre Lès Nancy, , France
Patients applied
Trial Officials
ROMINA MASTRONICOLA PERNA, MD
Principal Investigator
Institut de Cancérologie de Lorraine
Naoual BOUJEDAINI, PhD
Study Chair
Institut de Cancérologie de Lorraine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported